Amedisys Inc (NASDAQ:AMED) Insider David L. Kemmerly Sells 8,125 Shares

Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 8,125 shares of Amedisys stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $117.77, for a total value of $956,881.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David L. Kemmerly also recently made the following trade(s):

  • On Thursday, May 30th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The stock was sold at an average price of $113.48, for a total value of $567,400.00.
  • On Monday, May 20th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The stock was sold at an average price of $109.96, for a total value of $549,800.00.
  • On Friday, May 10th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The stock was sold at an average price of $115.17, for a total value of $575,850.00.
  • On Tuesday, May 7th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The stock was sold at an average price of $118.20, for a total value of $591,000.00.

Shares of NASDAQ AMED opened at $118.65 on Friday. Amedisys Inc has a 52 week low of $81.83 and a 52 week high of $140.91. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 32.69, a P/E/G ratio of 1.47 and a beta of 1.40.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.22. The firm had revenue of $467.34 million during the quarter, compared to the consensus estimate of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter last year, the company posted $0.79 EPS. On average, equities analysts forecast that Amedisys Inc will post 4.08 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on AMED shares. Craig Hallum decreased their price objective on Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a report on Friday, March 1st. They noted that the move was a valuation call. SunTrust Banks lifted their price objective on Amedisys to $145.00 and gave the stock a “buy” rating in a report on Friday, March 1st. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. ValuEngine lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 27th. Finally, Raymond James raised Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price objective for the company in a report on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $129.89.

Several institutional investors and hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC boosted its position in shares of Amedisys by 2.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 3,704 shares of the health services provider’s stock valued at $433,000 after acquiring an additional 95 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Amedisys by 2.0% during the 4th quarter. Jennison Associates LLC now owns 6,408 shares of the health services provider’s stock valued at $750,000 after acquiring an additional 126 shares during the last quarter. Alpha Quant Advisors LLC boosted its position in shares of Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after acquiring an additional 137 shares during the last quarter. ETRADE Capital Management LLC boosted its position in shares of Amedisys by 2.2% during the 4th quarter. ETRADE Capital Management LLC now owns 6,819 shares of the health services provider’s stock valued at $799,000 after acquiring an additional 148 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Amedisys by 9.9% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,813 shares of the health services provider’s stock valued at $222,000 after acquiring an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 86.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thestockobserver.com/2019/06/14/amedisys-inc-nasdaqamed-insider-david-l-kemmerly-sells-8125-shares.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: How a Back-End Load Mutual Fund Works

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.